GE Healthcare Technologies (GEHC) said Friday the NCCN clinical practice guidelines in oncology for doctors now recommend considering the use of fluoroestradiol, or FES, positron emission tomography, or PET, imaging in some individuals with lobular breast cancer.
The company said its cerianna injection is the only imaging agent approved by the US Food and Drug Administration to detect estrogen receptor positive breast cancer metastases, including lobular breast cancer.
GE Healthcare said invasive lobular cancer is the second most common type of breast cancer in the US.
Price: 70.05, Change: -1.48, Percent Change: -2.07
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.